by telrheum | Dec 3, 2024 | Connective Tissue Diease, Anti-Synthetase Syndrome, Interstitial Lung Disease, Systemic Sclerosis
The “Classification Criteria for Anti-Synthetase Syndrome (CLASS) Project” sought to develop new, standardized guidelines to diagnose Anti-Synthetase Syndrome (ASSD), a rare autoimmune condition that primarily affects muscles, joints, and lungs and is linked to...
by telrheum | Dec 3, 2024 | Gout, Uloric
Summary: Prolonged Plasma Urate-Lowering with PRX-115 This study explores a new medication, PRX-115, designed to lower uric acid levels in the blood. PRX-115 is a modified enzyme (PEGylated uricase) that breaks down uric acid, aimed at treating severe gout cases where...
by telrheum | Oct 6, 2024 | Osteoarthritis, Arthritis Supplements, Degenerative Arthritis, Orthopedic
This study explores the use of intra-articular (IA) liraglutide (LIRA), a glucagon-like peptide-1 (GLP-1) analog, for treating osteoarthritis (OA), a common age-related disease that causes chronic pain and restricts mobility. Current treatments, like corticosteroids...
by telrheum | Oct 6, 2024 | Uncategorized
This study investigates the role of B and T cells in kidney biopsies from patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), an autoimmune disease that primarily affects small blood vessels, leading to severe complications in organs...
by telrheum | Sep 29, 2024 | Ankylosing Spondylitis, Biologic Therapy, Spondyloarthritis
The study explored the long-term safety and effectiveness of Bimekizumab (BKZ), a monoclonal antibody designed to block two proteins involved in inflammation, IL-17A and IL-17F. This dual inhibition helps control the excessive inflammation seen in ankylosing...
